BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9844472)

  • 1. [Mechanisms of resistance in Pseudomonas aeruginosa].
    Cercenado Mansilla E; García Garrote F
    Rev Clin Esp; 1998 Sep; 198 Suppl 2():10-6. PubMed ID: 9844472
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antimicrobial drug therapy and microbial sensitivity tests: general concept of antibiotics].
    Miyazakin S; Yamaguchi K
    Rinsho Byori; 1997 Jul; Suppl 105():162-73. PubMed ID: 9379536
    [No Abstract]   [Full Text] [Related]  

  • 3. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
    Eagye KJ; Nicolau DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
    Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.
    Jung R; Fish DN; Obritsch MD; MacLaren R
    J Hosp Infect; 2004 Jun; 57(2):105-11. PubMed ID: 15183239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in Brazil.
    Viana Vieira V; Lourenço da Fonseca E; Paulo Vincente AC
    Clin Microbiol Infect; 2005 Nov; 11(11):937. PubMed ID: 16216114
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hospital infections caused by Pseudomonas aeruginosa. Significance in intensive therapy].
    Sidorenko SV; Gel'fand EB; Mamontova OA
    Anesteziol Reanimatol; 1999; (3):46-54. PubMed ID: 10458038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multiply resistant Pseudomonas aeruginosa in the pediatric field].
    Tabuki K
    Nihon Rinsho; 1991 Oct; 49(10):2387-92. PubMed ID: 1660948
    [No Abstract]   [Full Text] [Related]  

  • 9. [Evaluation of the sensitivity of clinical strains of Pseudomonas aeruginosa to aminoglycoside and beta-lactam antibiotics].
    Dzierzanowska D; Patzer J
    Med Dosw Mikrobiol; 1987; 39(2):105-10. PubMed ID: 3116356
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():17-32. PubMed ID: 15953020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibiotic resistant Pseudomonas aeruginosa].
    Gotoh N
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():196-201. PubMed ID: 12717971
    [No Abstract]   [Full Text] [Related]  

  • 12. IMP-1 metallo-beta-lactamase-producing Pseudomonas aeruginosa in a university hospital in the People's Republic of China.
    Wang CX; Mi ZH
    J Antimicrob Chemother; 2004 Dec; 54(6):1159-60. PubMed ID: 15537691
    [No Abstract]   [Full Text] [Related]  

  • 13. Stable carbapenem susceptibility rates among multidrug-resistant Acinetobacter spp. strains in a setting of high prevalence of carbapenem-resistant Pseudomonas aeruginosa.
    Zavascki AP; Soares FC; Superti SV; Silbert S; Silva FM; Barth AL
    Int J Antimicrob Agents; 2007 Aug; 30(2):187-9. PubMed ID: 17452093
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of antimicrobial drug combinations against Pseudomonas aeruginosa: beta-lactams and aminoglycosides.
    Martinetto P; Malcangi A; Penna R
    G Ital Chemioter; 1988; 35(1-3):17-21. PubMed ID: 3151486
    [No Abstract]   [Full Text] [Related]  

  • 15. First report of the carbapenem-resistant Pseudomonas aeruginosa producing IMP-7 metallo-beta-lactamase in Slovakia.
    Ohlasova D; Kmet V; Niks M
    Int J Antimicrob Agents; 2007 Oct; 30(4):370-1. PubMed ID: 17709230
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antibiotic resistance of some Pseudomonas aeruginosa isolates].
    Matinca D; Vancea D; Boboş C; Serban O
    Bacteriol Virusol Parazitol Epidemiol; 2003; 48(2-3):157-61. PubMed ID: 15341333
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa.
    Scheetz MH; Esterly JS; Malczynski M; Postelnick M; Qi C
    Diagn Microbiol Infect Dis; 2009 Aug; 64(4):465-7. PubMed ID: 19394788
    [No Abstract]   [Full Text] [Related]  

  • 18. Ventilator-associated pneumonia caused by Pseudomonas infection.
    Dunn M; Wunderink RG
    Clin Chest Med; 1995 Mar; 16(1):95-109. PubMed ID: 7768096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of pandrug-resistance of Pseudomonas aeruginosa].
    Shen JL; Zhu DM; Wang MG
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1859-62. PubMed ID: 19040025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
    Prasad SV; Ballal M; Shivananda PG
    Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.